Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease

Kathleen M. Hill, Berdine R. Martin, Meryl E. Wastney, George P. McCabe, Sharon Moe, Connie M. Weaver, Munro Peacock

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

Patients with chronic kidney disease (CKD) are given calcium carbonate to bind dietary phosphorus, reduce phosphorus retention, and prevent negative calcium balance; however, data are limited on calcium and phosphorus balance during CKD to support this. Here, we studied eight patients with stage 3 or 4 CKD (mean estimated glomerular filtration rate 36 ml/min) who received a controlled diet with or without a calcium carbonate supplement (1500 mg/day calcium) during two 3-week balance periods in a randomized placebo-controlled cross-over design. All feces and urine were collected during weeks 2 and 3 of each balance period and fasting blood, and urine was collected at baseline and at the end of each week. Calcium kinetics were determined using oral and intravenous 45 calcium. Patients were found to be in neutral calcium and phosphorus balance while on the placebo. Calcium carbonate supplementation produced positive calcium balance, did not affect phosphorus balance, and produced only a modest reduction in urine phosphorus excretion compared with placebo. Calcium kinetics demonstrated positive net bone balance but less than overall calcium balance, suggesting soft-tissue deposition. Fasting blood and urine biochemistries of calcium and phosphate homeostasis were unaffected by calcium carbonate. Thus, the positive calcium balance produced by calcium carbonate treatment within 3 weeks cautions against its use as a phosphate binder in patients with stage 3 or 4 CKD, if these findings can be extrapolated to long-term therapy.

Original languageEnglish
Pages (from-to)959-966
Number of pages8
JournalKidney International
Volume83
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Calcium Carbonate
Chronic Renal Insufficiency
Phosphorus
Calcium
Urine
Placebos
Fasting
Dietary Phosphorus
Glomerular Filtration Rate
Feces
Biochemistry
Cross-Over Studies
Homeostasis
Phosphates
Diet
Bone and Bones

ASJC Scopus subject areas

  • Nephrology

Cite this

Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. / Hill, Kathleen M.; Martin, Berdine R.; Wastney, Meryl E.; McCabe, George P.; Moe, Sharon; Weaver, Connie M.; Peacock, Munro.

In: Kidney International, Vol. 83, No. 5, 05.2013, p. 959-966.

Research output: Contribution to journalArticle

Hill, Kathleen M. ; Martin, Berdine R. ; Wastney, Meryl E. ; McCabe, George P. ; Moe, Sharon ; Weaver, Connie M. ; Peacock, Munro. / Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. In: Kidney International. 2013 ; Vol. 83, No. 5. pp. 959-966.
@article{d021ac123d104cfeae5e73ee93736214,
title = "Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease",
abstract = "Patients with chronic kidney disease (CKD) are given calcium carbonate to bind dietary phosphorus, reduce phosphorus retention, and prevent negative calcium balance; however, data are limited on calcium and phosphorus balance during CKD to support this. Here, we studied eight patients with stage 3 or 4 CKD (mean estimated glomerular filtration rate 36 ml/min) who received a controlled diet with or without a calcium carbonate supplement (1500 mg/day calcium) during two 3-week balance periods in a randomized placebo-controlled cross-over design. All feces and urine were collected during weeks 2 and 3 of each balance period and fasting blood, and urine was collected at baseline and at the end of each week. Calcium kinetics were determined using oral and intravenous 45 calcium. Patients were found to be in neutral calcium and phosphorus balance while on the placebo. Calcium carbonate supplementation produced positive calcium balance, did not affect phosphorus balance, and produced only a modest reduction in urine phosphorus excretion compared with placebo. Calcium kinetics demonstrated positive net bone balance but less than overall calcium balance, suggesting soft-tissue deposition. Fasting blood and urine biochemistries of calcium and phosphate homeostasis were unaffected by calcium carbonate. Thus, the positive calcium balance produced by calcium carbonate treatment within 3 weeks cautions against its use as a phosphate binder in patients with stage 3 or 4 CKD, if these findings can be extrapolated to long-term therapy.",
author = "Hill, {Kathleen M.} and Martin, {Berdine R.} and Wastney, {Meryl E.} and McCabe, {George P.} and Sharon Moe and Weaver, {Connie M.} and Munro Peacock",
year = "2013",
month = "5",
doi = "10.1038/ki.2012.403",
language = "English",
volume = "83",
pages = "959--966",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease

AU - Hill, Kathleen M.

AU - Martin, Berdine R.

AU - Wastney, Meryl E.

AU - McCabe, George P.

AU - Moe, Sharon

AU - Weaver, Connie M.

AU - Peacock, Munro

PY - 2013/5

Y1 - 2013/5

N2 - Patients with chronic kidney disease (CKD) are given calcium carbonate to bind dietary phosphorus, reduce phosphorus retention, and prevent negative calcium balance; however, data are limited on calcium and phosphorus balance during CKD to support this. Here, we studied eight patients with stage 3 or 4 CKD (mean estimated glomerular filtration rate 36 ml/min) who received a controlled diet with or without a calcium carbonate supplement (1500 mg/day calcium) during two 3-week balance periods in a randomized placebo-controlled cross-over design. All feces and urine were collected during weeks 2 and 3 of each balance period and fasting blood, and urine was collected at baseline and at the end of each week. Calcium kinetics were determined using oral and intravenous 45 calcium. Patients were found to be in neutral calcium and phosphorus balance while on the placebo. Calcium carbonate supplementation produced positive calcium balance, did not affect phosphorus balance, and produced only a modest reduction in urine phosphorus excretion compared with placebo. Calcium kinetics demonstrated positive net bone balance but less than overall calcium balance, suggesting soft-tissue deposition. Fasting blood and urine biochemistries of calcium and phosphate homeostasis were unaffected by calcium carbonate. Thus, the positive calcium balance produced by calcium carbonate treatment within 3 weeks cautions against its use as a phosphate binder in patients with stage 3 or 4 CKD, if these findings can be extrapolated to long-term therapy.

AB - Patients with chronic kidney disease (CKD) are given calcium carbonate to bind dietary phosphorus, reduce phosphorus retention, and prevent negative calcium balance; however, data are limited on calcium and phosphorus balance during CKD to support this. Here, we studied eight patients with stage 3 or 4 CKD (mean estimated glomerular filtration rate 36 ml/min) who received a controlled diet with or without a calcium carbonate supplement (1500 mg/day calcium) during two 3-week balance periods in a randomized placebo-controlled cross-over design. All feces and urine were collected during weeks 2 and 3 of each balance period and fasting blood, and urine was collected at baseline and at the end of each week. Calcium kinetics were determined using oral and intravenous 45 calcium. Patients were found to be in neutral calcium and phosphorus balance while on the placebo. Calcium carbonate supplementation produced positive calcium balance, did not affect phosphorus balance, and produced only a modest reduction in urine phosphorus excretion compared with placebo. Calcium kinetics demonstrated positive net bone balance but less than overall calcium balance, suggesting soft-tissue deposition. Fasting blood and urine biochemistries of calcium and phosphate homeostasis were unaffected by calcium carbonate. Thus, the positive calcium balance produced by calcium carbonate treatment within 3 weeks cautions against its use as a phosphate binder in patients with stage 3 or 4 CKD, if these findings can be extrapolated to long-term therapy.

UR - http://www.scopus.com/inward/record.url?scp=84877027844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877027844&partnerID=8YFLogxK

U2 - 10.1038/ki.2012.403

DO - 10.1038/ki.2012.403

M3 - Article

VL - 83

SP - 959

EP - 966

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 5

ER -